A2A Panelist

Updated: Feb 7, 2020

A2A Founder & CEO Edward Painter was a panelist at BIO Investor forum panel entitled "Applying artificial intelligence to improve therapy development today"

Biomea Fusion, Inc., a precision oncology company dedicated to developing innovative medicines targeting genomically defined alterations...

A2A Pharmaceuticals Inc. Today Announced a Multi-target Co-development Agreement With Daewoong Pharmaceutical for AI-enhanced Oncology...